203.95
+16.09
+(8.56%)
At close: 3:30:03 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
25,777,200
25,436,200
23,150,500
21,406,800
19,120,300
Cost of Revenue
5,515,700
6,116,100
5,342,100
4,588,800
4,840,900
Gross Profit
20,261,500
19,320,100
17,808,400
16,818,000
14,279,400
Operating Expense
19,309,900
19,404,900
16,753,500
16,519,500
14,402,900
Operating Income
951,600
-84,800
1,054,900
298,500
-123,500
Net Non Operating Interest Income Expense
-1,339,000
-1,055,800
-632,400
-290,000
-217,400
Pretax Income
-575,900
-1,222,600
-545,900
-42,500
-650,300
Tax Provision
521,800
311,900
-247,900
-222,600
1,001,000
Net Income Common Stockholders
-1,097,700
-1,534,500
-298,000
180,100
-1,651,300
Diluted NI Available to Com Stockholders
-1,097,700
-1,534,500
-298,000
180,100
-1,651,300
Basic EPS
-7.00
-9.79
-1.90
1.15
-10.53
Diluted EPS
-7.00
-9.79
-1.90
1.15
-10.53
Basic Average Shares
156,912.89
156,783.10
156,783.10
156,783.10
156,793.10
Diluted Average Shares
156,912.89
156,783.10
156,783.10
156,783.10
156,793.10
Rent Expense Supplemental
--
100,100
87,600
84,900
65,400
Total Expenses
24,825,600
25,521,000
22,095,600
21,108,300
19,243,800
Net Income from Continuing & Discontinued Operation
-1,097,700
-1,534,500
-298,000
180,100
-1,651,300
Normalized Income
-1,007,183
-1,462,840.62
61,800
262,700
-1,477,630
Interest Income
--
130,000
182,500
191,500
217,700
Interest Expense
1,417,300
1,134,100
743,900
392,200
390,300
Net Interest Income
-1,339,000
-1,055,800
-632,400
-290,000
-217,400
EBIT
841,400
-88,500
198,000
349,700
-260,000
EBITDA
3,837,900
3,020,100
3,005,200
3,425,600
2,819,400
Reconciled Cost of Revenue
5,515,700
6,116,100
5,342,100
4,588,800
4,840,900
Reconciled Depreciation
2,996,500
3,108,600
2,807,200
3,075,900
3,079,400
Net Income from Continuing Operation Net Minority Interest
-1,097,700
-1,534,500
-298,000
180,100
-1,651,300
Total Unusual Items Excluding Goodwill
-129,310
-96,200
-514,000
-118,000
-248,100
Total Unusual Items
-129,310
-96,200
-514,000
-118,000
-248,100
Normalized EBITDA
3,967,210
3,116,300
3,519,200
3,543,600
3,067,500
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-38,793
-24,540.62
-154,200
-35,400
-74,430
3/31/2021 - 4/22/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RPD.MU Royalty Pharma plc
28.20
-3.09%
2GH.BE Merus NV
36.80
+6.36%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
2HA.F Spero Therapeutics, Inc.
0.4965
-7.20%
P0F.F Egetis Therapeutics AB (publ)
0.3270
+2.35%
BT3.BE Lineage Cell Therapeutics Inc
0.3580
-2.72%
B9A.F BioArctic AB (publ)
14.71
-0.94%
7PO.F Poxel S.A.
0.5300
0.00%
HQ1.MU Oruka Therapeutics Inc. R
6.40
0.00%
PTN.DU Palatin Technologies Inc
0.2995
-25.50%